Insufficient protection by Neisseria meningitidis vaccination alone during eculizumab therapy
Open Access
- 1 October 2011
- journal article
- letter
- Published by Springer Nature in Pediatric Nephrology
- Vol. 26 (10), 1919-1920
- https://doi.org/10.1007/s00467-011-1929-3
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Immunogenicity of a Single Dose of Tetravalent Meningococcal Serogroups A, C, W-135, and Y Conjugate Vaccine Administered to 2- to 10-year-olds Is Noninferior to a Licensed-ACWY Polysaccharide Vaccine With an Acceptable Safety ProfileThe Pediatric Infectious Disease Journal, 2011
- aHUS caused by complement dysregulation: new therapies on the horizonPediatric Nephrology, 2010
- Long‐term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuriaAmerican Journal of Hematology, 2010
- Global epidemiology of meningococcal diseaseVaccine, 2009
- FDA Report: Eculizumab (Soliris®) for the Treatment of Patients with Paroxysmal Nocturnal HemoglobinuriaThe Oncologist, 2008
- Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuriaBlood, 2008
- Prevention of Meningococcal DiseaseNew England Journal of Medicine, 2006
- Meningococcal disease and its management in childrenBMJ, 2006